Patent · US Active

Nucleic acids for treatment of allergies

US10072053B2 · kind B2 · utility

0Cited by
8References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 31, 2017
Grant dateSep 11, 2018
Priority date—
Expiry dateJul 31, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/35
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides DNA vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (LAMP) and the targeting sequence of LAMP. The vaccines allow for presentation of properly configured three dimensional epitopes for production of an immune response. The vaccines can be multivalent molecules, and/or can be provided as part of a multivalent vaccine containing two or more DNA constructs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.